Neurology 2000;54:193
© 2000 American Academy of Neurology
Articles
Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS
A. Kracke, MD,
P. von Wussow, MD,
A. N. Al-Masri, MSc,
G. Dalley,
A. Windhagen, MD and
F. Heidenreich, MD
From the Departments of Neurology (Drs. Kracke, Dalley, Windhagen, Heidenreich) and Rheumatology (Dr. Al-Masri), Hannover Medical School, Hannover, Germany; and the Sophien Klinik Hannover (Dr. von Wussow), Hannover, Germany.
Address correspondence and reprint requests to Dr. F. Heidenreich, Department of Neurology-OE 7210, Hannover Medical School, D-30623 Hannover, Germany; e-mail: heidenreich.fedor{at}mh-hannover.de
OBJECTIVE: To correlate Mx protein (Mx) levels in lysed blood leukocytes with the clinical response to interferon (IFN) beta-1b (IFNß-1b) in relapsing–remitting MS (RR-MS) patients for monitoring treatment.
BACKGROUND: Intracellular Mx expression is exclusively induced by the type I IFNs (IFN- , -ß, and - ) or by viruses and is strongly increased under IFN treatment. Quantitative determination of Mx allows objective assessment of biological effects of IFN.
METHODS: Mx protein levels were measured in blood leukocyte lysates from IFNß-1b-treated RR-MS patients by ELISA and correlated to clinical parameters, including relapse rate and clinical deterioration.
RESULTS: In stable IFNß-1b-treated MS patients, Mx levels were significantly increased compared to patients with or without immunosuppressive treatment. In IFNß-1b-treated MS patients during relapse, Mx levels were significantly lower than during stable phases of the disease. Mean values of Mx (MVMx) over time of treatment in patients with a reduction of relapse rate were significantly higher than in patients without response.
CONCLUSION: Mx levels in lysed blood cells may represent a useful surrogate marker for IFNß-1b activity corresponding to the clinical response during treatment of MS.
Key words: MS—Mx proteins—Interferon beta
This article has been cited by other articles:
|
|
|
|
 
A. W. Chiu, N. Richert, M. Ehrmantraut, J. Ohayon, S. Gupta, G. Bomboi, D. Gaindh, F. K. Cantor, J. A. Frank, H. F. McFarland, et al.
Heterogeneity in Response to Interferon Beta in Patients With Multiple Sclerosis: A 3-Year Monthly Imaging Study
Arch Neurol,
January 1, 2009;
66(1):
39 - 43.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Rio, A Rovira, M Tintore, E Huerga, C Nos, N Tellez, C Tur, M Comabella, and X Montalban
Relationship between MRI lesion activity and response to IFN-{beta} in relapsing-remitting multiple sclerosis patients
Multiple Sclerosis,
May 1, 2008;
14(4):
479 - 484.
[Abstract]
[PDF]
|
|
|
|
|
|
|
K. Hamamcioglu and A. Reder
Interferon-{beta} regulates cytokines and BDNF: greater effect in relapsing than in progressive multiple sclerosis
Multiple Sclerosis,
May 1, 2007;
13(4):
459 - 470.
[Abstract]
[PDF]
|
|
|
|
|
|
|
E Portaccio, V Zipoli, G Siracusa, S Sorbi, and M P Amato
Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria
Multiple Sclerosis,
June 1, 2006;
12(3):
281 - 286.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F Gilli, F Marnetto, M Caldano, A Sala, S Malucchi, M Capobianco, and A Bertolotto
Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1
Multiple Sclerosis,
February 1, 2006;
12(1):
47 - 57.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A Bertolotto, A Sala, S Malucchi, F Marnetto, M Caldano, A Di Sapio, M Capobianco, and F Gilli
Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies
J. Neurol. Neurosurg. Psychiatry,
September 1, 2004;
75(9):
1294 - 1299.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Malucchi, A. Sala, F. Gilli, R. Bottero, A. Di Sapio, M. Capobianco, and A. Bertolotto
Neutralizing antibodies reduce the efficacy of {beta}IFN during treatment of multiple sclerosis
Neurology,
June 8, 2004;
62(11):
2031 - 2037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R. Pachner, A. Bertolotto, and F. Deisenhammer
Measurement of MxA mRNA or protein as a biomarker of IFN{beta} bioactivity: Detection of antibody-mediated decreased bioactivity (ADB)
Neurology,
November 11, 2003;
61(90095):
S24 - 26.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
E. Waubant, S. Vukusic, L. Gignoux, F. D. Dubief, I. Achiti, S. Blanc, C. Renoux, and C. Confavreux
Clinical characteristics of responders to interferon therapy for relapsing MS
Neurology,
July 22, 2003;
61(2):
184 - 189.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bertolotto, F. Gilli, A. Sala, M. Capobianco, S. Malucchi, E. Milano, F. Melis, F. Marnetto, R. L.P. Lindberg, R. Bottero, et al.
Persistent neutralizing antibodies abolish the interferon {beta} bioavailability in MS patients
Neurology,
February 25, 2003;
60(4):
634 - 639.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Kob, J Harvey, F Schautzer, S Kascha, D Bibl, R Egg, M Reindl, T Berger, and F Deisenhammer
A novel and rapid assay for the detection of neutralizing antibodies against interferon-beta
Multiple Sclerosis,
February 1, 2003;
9(1):
32 - 35.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Gromov, G. L. Skovgaard, H. Palsdottir, I. Gromova, M. Ostergaard, and J. E. Celis
Protein Profiling of the Human Epidermis from the Elderly Reveals Up-regulation of a Signature of Interferon-{gamma}-induced Polypeptides That Includes Manganese-superoxide Dismutase and the p85{beta} Subunit of Phosphatidylinositol 3-Kinase
Mol. Cell. Proteomics,
February 1, 2003;
2(2):
70 - 84.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Burks, B. G. Arnason, P. K. Coyle, C. C. Ford, A. Noronha, and K. W. Rammohan
Issues and Practices in Multiple Sclerosis
Neurorehabil Neural Repair,
December 1, 2002;
16(4):
307 - 320.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Muller-Doblies, M. Ackermann, and A. Metzler
In Vitro and In Vivo Detection of Mx Gene Products in Bovine Cells following Stimulation with Alpha/Beta Interferon and Viruses
Clin. Vaccine Immunol.,
November 1, 2002;
9(6):
1192 - 1199.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Abel, M. J. Alegria-Hartman, K. Rothaeusler, M. Marthas, and C. J. Miller
The Relationship between Simian Immunodeficiency Virus RNA Levels and the mRNA Levels of Alpha/Beta Interferons (IFN-{alpha}/{beta}) and IFN-{alpha}/{beta}-Inducible Mx in Lymphoid Tissues of Rhesus Macaques during Acute and Chronic Infection
J. Virol.,
August 15, 2002;
76(16):
8433 - 8445.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-M. Vallittu, M. Halminen, J. Peltoniemi, J. Ilonen, I. Julkunen, A. Salmi, J.-P. Eralinna, and the Finnish Beta-Interferon Study Group
Neutralizing antibodies reduce MxA protein induction in interferon- beta-1a-treated MS patients
Neurology,
June 25, 2002;
58(12):
1786 - 1790.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Charleston, M. D. Fray, S. Baigent, B. V. Carr, and W. I. Morrison
Establishment of persistent infection with non-cytopathic bovine viral diarrhoea virus in cattle is associated with a failure to induce type I interferon
J. Gen. Virol.,
August 1, 2001;
82(8):
1893 - 1897.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. T. Reder and J. P. Antel
Injecting rationale into interferon-{beta} therapy
Neurology,
June 13, 2000;
54(11):
2034 - 2035.
[Full Text]
[PDF]
|
|
|
|
